In New England Journal of Medicine editorial, Fred Hutchinson Cancer Research Center’s Dr. Fred Appelbaum argues adult stem cells harvested from bone marrow rather than blood of unrelated donors are best for reducing graft-vs.-host disease risk
Case is first to show safety and effectiveness of using infection-fighting T cells alone to put late-stage melanoma into long-term remission
June 23, 2008
| By Dean Forbes
Scientists from Fred Hutchinson Cancer Research Center describe the first successful use of a human patient’s cloned infection-fighting T-cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission
With greater affluence comes a global increase in breast-cancer risk, reports cancer biology researcher Peggy Porter
Jan. 28, 2008
As Dr. Peggy Porter from Fred Hutchinson Cancer Research Center reports in her Jan. 17, New England Journal of Medicine “Perspective,” the most widely cited reasons for the global rise of breast-cancer incidences and related deaths are increasing prosperity and the “Westernization” of traditional lifestyles.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.